Abstract
Treatment of hepatitis C virus (HCV) infection with ledipasvir/ sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (Ptrend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.
| Original language | English |
|---|---|
| Journal | Open Forum Infectious Diseases |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| State | Published - Dec 1 2014 |
Bibliographical note
Publisher Copyright:© The Author 2014.
Funding
This research was supported by the Intramural Research Program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics).
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | |
| National Childhood Cancer Registry – National Cancer Institute | |
| National Cancer Institute Division of Cancer Epidemiology and Genetics |
Keywords
- Clinical trial
- Cost-effectiveness
- Direct-acting antiviral agents
- Gender
- Hepatitis C virus
- IFNL4
ASJC Scopus subject areas
- Oncology
- Clinical Neurology
